CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Results of Operations and Financial Condition

CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition

Story continues below

On February 13, 2019, Cambrex Corporation issued a press release announcing its financial results for the fourth quarter and full year 2018.The Press Release is attached to this Form 8-K as Exhibit 99.1.

Such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other document under the Securities Act of 1933.

Item 9.01 – Financial Statements and Exhibits

(d)Exhibits

Exhibit 99.1 – Cambrex Corporation Press Release Dated February 13, 2019

Such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other document under the Securities Act of 1933.

CAMBREX CORP Exhibit
EX-99.1 2 cbm-ex991_8.htm EX-99.1 cbm-ex991_8.htm Exhibit 99.1       NEWS RELEASE     Cambrex Corporation | One Meadowlands Plaza | East Rutherford,…
To view the full exhibit click here

About CAMBREX CORPORATION (NYSE:CBM)

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States. The Company’s business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and other fine chemicals. The Company’s products and services are sold around the world under trademarks that are owned by the Company. This includes Profarmaco, which is registered around the world as a word and design mark. Its products are sold through a combination of direct sales and independent agents.

An ad to help with our costs